<DOC>
	<DOCNO>NCT00091156</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes necessary growth . It yet know whether give gefitinib initial chemotherapy effective delay recurrence non-small cell lung cancer . PURPOSE : This randomized phase III trial study gefitinib see well work compare placebo delay tumor recurrence patient undergone initial chemotherapy stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Gefitinib After Chemotherapy Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient stage IIIB IV non-small cell lung cancer progress prior first-line palliative induction chemotherapy treat adjuvant gefitinib v placebo . Secondary - Compare progression-free survival patient treat regimen . - Determine safety toxicity gefitinib patient . OUTLINE : This randomize , placebo-controlled , double-blind , multicenter study . Patients stratify accord initial disease stage ( IIIB v IV ) , WHO performance status end prior first-line palliative induction chemotherapy ( 0-1 v 2 ) , best patient response prior first-line palliative induction chemotherapy ( objective response v stable disease ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral gefitinib daily . - Arm II : Patients receive oral placebo daily . In arm , treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : A total 598 patient ( 299 per treatment arm ) accrue study within 8.5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer meet 1 follow stage criterion : Stage IIIB Pleural fluid and/or supraclavicular node allow provided patient eligible consolidation radiotherapy Stage IV disease No disease progression 26 course prior platinumcontaining firstline palliative induction chemotherapy Brain metastases allow provided patient asymptomatic cranial irradiation complete least 4 week ago PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Pulmonary No history , sign , symptom clinically active interstitial lung disease Patients chronic , stable , asymptomatic radiographic change eligible Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychological , familial , sociological , geographical condition would preclude study compliance followup No malignant disease within past 5 year except basal cell skin cancer adequately treat superficial carcinoma cervix PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics Recovered prior chemotherapy ( alopecia allow ) No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify Other No prior epidermal growth factor receptor inhibitor No concurrent administration follow drug : Phenytoin Carbamazepine Rifampin Phenobarbital Hypericum perforatum ( St. John 's wort ) No concurrent anticancer therapy No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>